Skip to main content
SpringerLink
Log in

Clarification of Terminology in Drug Safety

Drug Safety Aims and scope Submit manuscript

Cite this article

Abstract

Nomenclature surrounding drug safety needs to be clear and unambiguous, so that patients, prescribers, manufacturers, and regulators can all understand each other. In particular, it needs to make it clear how adverse events and drug therapy are related to one another, how they are best classified, and their frequency, intensity and seriousness.

In this article, we therefore discuss and define terms used in the field of drug safety, particularly terms that are sometimes misunderstood or misused, including medicinal product, pharmaceutical formulation, excipient, adverse event (or experience) and adverse drug reaction (or effect). We also discuss terms used to define the seriousness, intensity, and risk of adverse reactions, and their classification.

Instead of creating definitions from scratch, as is commonly done, we have taken the novel approach of critically examining definitions that have been proposed or widely used and have formulated new or modified definitions based on a logical appraisal of their merits and demerits. We hope that these definitions will lead to discussion that will allow a corpus of satisfactory definitions to be widely agreed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Table II
Table III
Table IV
Table V
Table VI
Table VII

References

  1. Buetow SA, Sibbald B, Cantrill JA, et al. Appropriateness in health care: application to prescribing. Soc Sci Med 1997; 45: 261–71

    Article  PubMed  CAS  Google Scholar 

  2. Aronson JK. What is a clinical trial? Br J Clin Pharmacol 2004; 58: 61–3

    Article  Google Scholar 

  3. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the member states relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use. Off J Eur Commun 2001; L121: 34–44 [online]. Available from URL: http://www.eortc.be/Services/Doc/clinical-EUdirective-04-April-01.pdf [Accessed 2003 Sep 26]

  4. Inman WH. Postmarketing surveillance of adverse drug reactions in general practice. I: search for new methods. BMJ (Clin Res Ed) 1981; 282: 1131-2. II: Prescription-event monitoring at the University of Southampton. BMJ (Clin Res Ed) 1981; 282: 1216–7

    Article  CAS  Google Scholar 

  5. Kramer MS, Leventhal JM, Hutchinson TA, et al. An algorithm for the operational assessment of adverse drug reactions. I: Background, description, and instructions for use. JAMA 1979; 242: 623–32

    Article  PubMed  CAS  Google Scholar 

  6. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: implications for prevention. ADE Prevention Study Group. JAMA 1995; 274: 29–34

    Article  PubMed  CAS  Google Scholar 

  7. Dunn N. 10-minute consultation: adverse drug event. BMJ 2003; 326: 1018

    Article  PubMed  Google Scholar 

  8. World Health Organization. International drug monitoring: the role of national centres. Technical Report Series No 498. Geneva: WHO, 1972

  9. Laurence D, editor, Carpenter J, contributor. A dictionary of pharmacology and allied topics. Amsterdam: Elsevier, 1998

    Google Scholar 

  10. Stephens MBD, Talbot JCC, Routledge PA, editors. The detection of new adverse drug reactions. 4th ed. London: Macmillan, 1998: 32–44

    Google Scholar 

  11. Ferner RE, Aronson JK. Errors in prescribing, preparing, and giving medicines: definition, classification, and prevention. In: Aronson JK, editor. Side effects of drugs. Annual 22. Amsterdam: Elsevier, 1999

    Google Scholar 

  12. Edwards IR, Aronson JK. Adverse drug reactions: definitions, classification, diagnosis, management, surveillance. Lancet 2000; 356: 1255–60

    Article  PubMed  CAS  Google Scholar 

  13. Hartigan-Go KY, Wong JQ. Inclusion of therapeutic failures as adverse drug reactions. In: Aronson JK, editor. Side effects of drugs. Annual 23. Amsterdam: Elsevier, 2000: xxvii–xxxiii

    Google Scholar 

  14. Wayne EJ. Problems of toxicity in clinical medicine. In: Walpole AL, Spinks A, editors. The evaluation of drug toxicity. London: J & A Churchill Ltd, 1958: 1–11

    Google Scholar 

  15. Levine RR. Factors modifying the effects of drugs in individuals. In: Pharmacology: drug actions and reactions. Boston (MA): Little, Brown and Co, 1973: 261–91

    Google Scholar 

  16. Wade OL, Beeley L. Adverse reactions to drugs. 2nd ed. London: William Heinemann Medical Books Ltd, 1976: Chapter II

    Google Scholar 

  17. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. Oxford: Oxford University Press, 1977: 44

  18. Rawlins MD, Thompson JW. Pathogenesis of adverse drug reactions. In: Davies DM, editor. Textbook of adverse drug reactions. 2nd ed. Oxford: Oxford University Press, 1981: 11

  19. Grahame-Smith DG, Aronson JK. The Oxford textbook of clinical pharmacology and drug therapy. Oxford: Oxford University Press, 1984: 134

  20. Hoigné R, Jaeger MD, Wymann R, et al. Time pattern of allergic reactions to drugs. Agents Actions Suppl 1990; 29: 39–58

    Article  PubMed  Google Scholar 

  21. Park BK, Pirmohamed M, Kitteringham NR. Idiosyncratic drug reactions: a mechanistic evaluation of risk factors. Br J Clin Pharmacol 1992; 34: 377–95

    Article  PubMed  CAS  Google Scholar 

  22. Laurence DR, Bennett PN. Clinical pharmacology. Edinburgh: Churchill Livingstone, 1992: 121–2

    Google Scholar 

  23. Ferner R, Mann RD. Drug safety and pharmacovigilance. In: Page C, Curtis MJ, Sutter MC, et al., editors. Integrated pharmacology. 1st ed. London: Mosby, 1997: 83–90

    Google Scholar 

  24. Aronson JK. Evidence-based medicine and the principles of drug therapy. Chapter 2. In: Haslett C, Chilvers ER, Boon NA, et al., editors. 19th ed. Davidson’s textbook of medicine. Edinburgh: Churchill Livingstone, 2002

    Google Scholar 

  25. Aronson JK, Ferner RE. Joining the DoTS: classifying adverse drug reactions by dose responsiveness, time course, and susceptibility. BMJ 2003; 327: 1222–5

    Article  PubMed  CAS  Google Scholar 

  26. Rawlins MD. Clinical pharmacology: adverse reactions to drugs. BMJ (Clin Res Ed) 1981; 282: 974–6

    Article  CAS  Google Scholar 

  27. Rawlins MD, Thomas SHL. Mechanisms of adverse drug reactions. In: Davies DM, Ferner RE, De Glanville H, editors. Davies’s textbook of adverse drug reactions. 5th ed. London: Chapman & Hall Medical, 1998: 40

  28. Frenz DA. Interpreting atmospheric pollen counts for use in clinical allergy: allergic symptomology. Ann Allergy Asthma Immunol 2001; 86: 150–7

    Article  PubMed  CAS  Google Scholar 

  29. Troisi CL, Heiberg DA, Hollinger FB. Normal immune response to hepatitis B vaccine in patients with Down’s syndrome: a basis for immunization guidelines. JAMA 1985; 254: 3196–9

    Article  PubMed  CAS  Google Scholar 

  30. Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001; 345: 804–9

    Article  PubMed  CAS  Google Scholar 

  31. Friedmann PS, Moss C, Shuster S, et al. Quantitative relationships between sensitising dose of DNCB and reactivity in normal subjects. Clin Exp Immunol 1983; 53: 709–15

    PubMed  CAS  Google Scholar 

  32. Cameron HA, Ramsay LE. The lupus syndrome induced by hydralazine: a common complication with low dose treatment. BMJ (Clin Res Ed) 1984; 289: 410–2

    Article  CAS  Google Scholar 

  33. Smith SE, Rawlins MD. Variability in human drug response. London: Butterworths, 1973

    Google Scholar 

  34. Wallace MR, Mascola JR, Oldfield EC. Red man syndrome: incidence, etiology and prophylaxis. J Infect Dis 1991; 164: 1180–5

    Article  PubMed  CAS  Google Scholar 

  35. Alderman CP. Adverse effects of the angiotensin-converting enzyme inhibitors. Ann Pharmacother 1996; 30: 55–61

    PubMed  CAS  Google Scholar 

  36. Saxon A, Beall GN, Rohr AS, et al. Immediate hypersensitivity reactions to beta-lactam antibiotics. Ann Intern Med 1987; 107: 204–15

    PubMed  CAS  Google Scholar 

  37. Geyman JP, Erickson S. The ampicillin rash as a diagnostic and management problem: case reports and literature review. J Fam Pract 1978; 7: 493–6

    PubMed  CAS  Google Scholar 

  38. Li KL, Huang HS, Wang PW, et al. Agranulocytosis associated with anti-thyroid drug in patients with Graves’ thyrotoxicosis: report of 11 cases. Changgeng Yi Xue Za Zhi 1991; 14: 168–73

    PubMed  CAS  Google Scholar 

  39. Zornberg GL, Jick H. Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study. Lancet 2000; 356: 1219–23

    Article  PubMed  CAS  Google Scholar 

  40. Hektoen L. Allergy or anaphylaxis in experiment and disease. JAMA 1912; 58: 1081–8

    Article  Google Scholar 

  41. Simpson J, Weiner E, editors. The Oxford English Dictionary. 2nd ed. Oxford: Oxford University Press, 1989

    Google Scholar 

  42. Rosenheim ML, Moulton R, editors. Sensitivity reactions to drugs. Oxford: Blackwells Scientific Publications, 1958: 4

  43. Hoigné RV. Should “idiosyncrasy” be defined as equivalent to “type B” adverse drug reactions? Pharmacoepidemiol Drug Saf 1997; 6: 213

    Article  PubMed  Google Scholar 

  44. Dorland’s Illustrated Medical Dictionary. 30th ed. Philadelphia (PA): Saunders, 2003

  45. David TJ. Adverse reactions and intolerance to foods. Br Med Bull 2000; 56: 34–50

    Article  PubMed  CAS  Google Scholar 

  46. Venulet J. Monitoring adverse reactions to drugs. In: Jucken E, editor. Progress in drug research. Basle: Berghausen Verlag, 1977

    Google Scholar 

  47. Tangrea JA, Adrianza ME, McAdams M. A method for the detection and management of adverse events in clinical trials. Drug Inf J 1991; 25: 63–80

    Article  Google Scholar 

  48. Assenzo JR, Sho VS. Use of statistics in the analysis of side-effect data from clinical trials of psychoactive agents. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 543–50

    Article  PubMed  CAS  Google Scholar 

  49. Grohmann R, Rütter E, Sassim N, et al. Adverse effects of clozapine. Psychopharmacology 1989; 99: S101–4

    Article  PubMed  Google Scholar 

  50. Karch FE, Lasagna L. Adverse drug reactions. JAMA 1975; 234: 1236–41

    Article  PubMed  CAS  Google Scholar 

  51. World Health Organization. Letter MIO/372/2(A). Geneva: World Health Organization, 1991

  52. Meyboom RHB, Royer RJ. Causality classification at pharmacovigilance centres in the European Community. Pharmacoepidemiol Drug Saf 1992; 1: 87–97

    Article  Google Scholar 

  53. Hutchinson TA, Leventhal JM, Kramer MS, et al. An algorithm for the operational assessment of adverse drug reactions. II: Demonstration of reproducibility and validity. JAMA 1979; 242: 633–8

    Article  PubMed  CAS  Google Scholar 

  54. Leventhal JM, Hutchinson TA, Kramer MS, et al. An algorithm for the operational assessment of adverse drug reactions. III: Results of tests among clinicians. JAMA 1979; 242: 1991–4

    Article  PubMed  CAS  Google Scholar 

  55. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability for adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45

    Article  PubMed  CAS  Google Scholar 

  56. Lanctot KL, Naranjo CA. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin Pharmacol Ther 1995; 58: 692–8

    Article  PubMed  CAS  Google Scholar 

  57. Stephens MDB. The diagnosis of adverse medical events associated with drug treatment. Adverse Drug React Acute Poisoning Rev 1987; 1: 1–35

    Google Scholar 

  58. Meyboom RH, Hekster YA, Egberts AC, et al. Causal or casual? The role of causality assessment in pharmacovigilance. Drug Saf 1997; 17: 374–89

    Article  PubMed  CAS  Google Scholar 

  59. Bryant GD, Norman GR. Expressions of probability: words and numbers [letter]. N Engl J Med 1980; 302: 411

    PubMed  CAS  Google Scholar 

  60. Kong A, Barnett GO, Mosteller F, et al. How medical professionals evaluate expressions of probability. N Engl J Med 1986; 315: 740–4

    Article  PubMed  CAS  Google Scholar 

  61. Calman KC, Royston GDH. Risks language and dialects. BMJ 1997; 315: 939–42

    Article  PubMed  CAS  Google Scholar 

  62. Paling J. Strategies to help patients understand risks. BMJ 2003; 327: 745–8

    Article  PubMed  Google Scholar 

  63. Edwards A. Communicating risk through analogies [letter]. BMJ 2003; 327: 749

    Article  PubMed  Google Scholar 

  64. Royal Society Study Group. Risk assessment. London: The Royal Society, 1983

  65. Lindquist M, Edwards IR, Bate A, et al. From Association to Alert: a revised approach to international signal analysis. Pharmacoepidemiol Drug Saf 1999; 8: S15–25

    Article  PubMed  Google Scholar 

  66. Bate A, Lindquist M, Edwards IR, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 1998; 54: 315–21

    Article  PubMed  CAS  Google Scholar 

  67. Orre R, Lansner A, Bate A, et al. Bayesian neural networks with confidence estimations applied to data mining. Comput Stat Data Analysis 2000; 34: 473–93

    Article  Google Scholar 

  68. Lindquist M, Stahl M, Bate A, et al. A retrospective valuation of a data mining approach to aid finding new adverse drug reaction signals in the WHO international database. Drug Saf 2000; 23: 533–42

    Article  PubMed  CAS  Google Scholar 

  69. Jick H. The discovery of drug-induced illness. N Engl J Med 1977; 296: 481–5

    Article  PubMed  CAS  Google Scholar 

  70. Venning GR. Validity of anecdotal reports of suspected adverse drug reactions: the problem of false alarms. BMJ (Clin Res Ed) 1982; 284: 249–52

    Article  CAS  Google Scholar 

  71. Kenney RM. Between never and always. N Engl J Med 1981; 305: 1097–8

    PubMed  CAS  Google Scholar 

  72. Toogood JH. What do we mean by “usually”? [letter]. Lancet 1980; I: 1094

    Article  Google Scholar 

  73. Roberts DE, Gupta G. How medical professionals evaluate expressions of probability [letter]. N Engl J Med 1987; 316: 550

    Google Scholar 

  74. Marion MN, Simon P. Signification des adverbes utilises pour indiquer la frequence des effets secondaries d’un medicament. Therapie 1984; 39: 4762–3

    Google Scholar 

  75. Mapes REA. Verbal and numerical estimates of probability in therapeutic contexts. Soc Sci Med 1979; 13A: 277–82

    PubMed  CAS  Google Scholar 

  76. Calman KC. Cancer: science and society and the communication of risk. BMJ 1996; 313: 799–802

    Article  PubMed  CAS  Google Scholar 

  77. Wood SM, Coulson R. Adverse Drug Reactions On-line Information Tracking (ADROIT). Pharm Med 1993; 7: 203–13

    Google Scholar 

  78. Brown EG. Effects of coding dictionary on signal generation: a consideration of use of MedDRA compared with WHO-ART. Drug Saf 2002; 25: 445–52

    Article  PubMed  Google Scholar 

  79. Wang AY, Sable JH, Spackman KA. The SNOMED clinical terms development process: refinement and analysis of content. Proc AMIA Symp 2002: 9

  80. Council for International Organizations of Medical Sciences. Basic requirements for the use of terms for reporting adverse drug reactions. Pharmacoepidemiol Drug Saf 1992; 1: 39’45

    Google Scholar 

  81. Bankowski Z, Bruppacher R, Crusius I, Gallagher J, Kremer G, Venulet J, editors. Reporting adverse drug reactions: definitions of terms and criteria for their use. Geneva: CIOMS, 1999

    Google Scholar 

  82. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999; 20: 109–17

    Article  PubMed  CAS  Google Scholar 

  83. Johansson SG, Hourihane JO, Bousquet J, et al. A revised nomenclature for allergy: an EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813–24

    Article  PubMed  CAS  Google Scholar 

  84. Herxheimer A. Benefit, risk and harm. Aust Presc 2001; 24: 18

    Google Scholar 

  85. Sandercock P, Berge E, Dennis M, et al. A systematic review of the effectiveness, cost-effectiveness and barriers to implementation of thrombolytic and neuroprotective therapy for acute ischaemic stroke in the NHS. Health Technol Assess 2002; 6: 1–112

    PubMed  CAS  Google Scholar 

  86. Hunink MG, Bult JR, de Vries J, et al. Uncertainty in decision models analyzing cost-effectiveness: the joint distribution of incremental costs and effectiveness evaluated with a nonparametric bootstrap method. Med Decis Making 1998; 18: 337–46

    Article  PubMed  CAS  Google Scholar 

  87. World Health Organization. Safety of medicines: a guide to detecting and reporting adverse drug reactions [online]. Available from URL: http://www.who.int/medicines/library/qsm/who-edm-qsm-2002-2/esd_safety.pdf [Accessed 2003 Sep 26]

  88. Orme ML’E. The Debendox saga. BMJ (Clin Res Ed) 1985; 291: 918–9

    Article  CAS  Google Scholar 

  89. Mazzotta P, Magee LA. A risk-benefit assessment of pharmacological and nonpharmacological treatments for nausea and vomiting of pregnancy. Drugs 2000; 59: 781–800

    Article  PubMed  CAS  Google Scholar 

  90. Delamothe T. Reporting adverse drug reactions. BMJ 1992; 304: 465

    Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this study. The authors have no conflicts of interest that are directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. University Department of Clinical Pharmacology, Radcliffe Infirmary, Woodstock Road, Oxford, OX2 6HE, UK

    Jeffrey K. Aronson

  2. West Midlands Centre for Adverse Drug Reaction Reporting, City Hospital, Birmingham, UK

    Robin E. Ferner

Authors
  1. Jeffrey K. Aronson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robin E. Ferner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jeffrey K. Aronson.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aronson, J.K., Ferner, R.E. Clarification of Terminology in Drug Safety. Drug-Safety 28, 851–870 (2005). https://doi.org/10.2165/00002018-200528100-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200528100-00003

Keywords

search

Navigation